JP2009505973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009505973A5 JP2009505973A5 JP2008525637A JP2008525637A JP2009505973A5 JP 2009505973 A5 JP2009505973 A5 JP 2009505973A5 JP 2008525637 A JP2008525637 A JP 2008525637A JP 2008525637 A JP2008525637 A JP 2008525637A JP 2009505973 A5 JP2009505973 A5 JP 2009505973A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- aryl
- alkyl
- optionally substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70643105P | 2005-08-09 | 2005-08-09 | |
| GB0516439A GB0516439D0 (en) | 2005-08-10 | 2005-08-10 | EP2 receptor agonists |
| PCT/GB2006/002979 WO2007017687A2 (en) | 2005-08-09 | 2006-08-09 | Ep2 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009505973A JP2009505973A (ja) | 2009-02-12 |
| JP2009505973A5 true JP2009505973A5 (enExample) | 2009-09-03 |
Family
ID=37671407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525637A Pending JP2009505973A (ja) | 2005-08-09 | 2006-08-09 | Ｅｐ２受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8080567B2 (enExample) |
| EP (1) | EP1951701A2 (enExample) |
| JP (1) | JP2009505973A (enExample) |
| AU (1) | AU2006277786B2 (enExample) |
| CA (1) | CA2618486A1 (enExample) |
| WO (1) | WO2007017687A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190509T1 (hr) * | 2008-03-12 | 2019-05-03 | Ube Industries, Ltd. | Spoj piridilaminooctene kiseline |
| PT2415763E (pt) | 2009-03-30 | 2016-03-30 | Ube Industries | Composição farmacêutica para tratamento ou prevenção do glaucoma |
| EP2755944B1 (en) * | 2011-09-16 | 2017-06-14 | Sanofi | Biarylderivatives,their preparation and their therapeutic application |
| WO2013164326A1 (en) * | 2012-05-03 | 2013-11-07 | Takeda Gmbh | Novel ep2 receptor agonists |
| BR112015024743A2 (pt) | 2013-03-28 | 2017-07-18 | Ube Industries | composto de biarila substituída |
| CN105555766A (zh) * | 2013-07-18 | 2016-05-04 | 诺华股份有限公司 | 作为补体因子d抑制剂的氨基甲基-联芳基衍生物及其应用 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP2024016311A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | Ｅｐ２アンタゴニスト |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| AU2022418436A1 (en) * | 2021-12-20 | 2024-07-11 | Nimml Institute | Immunoregulatory compounds |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9418483D0 (en) | 1994-09-14 | 1994-11-02 | British Tech Group | Compound for use in pre-term labour |
| US5576347A (en) | 1994-11-14 | 1996-11-19 | Sredni; Benjamin | Method of treating gastric ulcers |
| DK0951282T3 (da) | 1996-12-20 | 2008-07-14 | Pfizer | Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister |
| ATE237587T1 (de) | 1997-02-10 | 2003-05-15 | Ono Pharmaceutical Co | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten |
| US5939332A (en) | 1998-02-27 | 1999-08-17 | Roche Diagnostics Corp. | Phencyclidine analogs for immunoassay |
| DE69926148D1 (en) | 1998-11-09 | 2005-08-18 | Black James Foundation | Gastrin und cholecystokinin rezeptor ligande |
| US6121253A (en) | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
| SE9900025D0 (sv) | 1999-01-08 | 1999-01-08 | Synphora Ab | Method and composition for treatment of female sexual dysfunction |
| AP2002002555A0 (en) | 1999-12-22 | 2002-06-30 | Pfizer Prod Inc | EP4 Receptor selective agonists in the treatment of osteoporosis. |
| GB0011098D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| JP2005507413A (ja) | 2001-10-26 | 2005-03-17 | アラーガン インコーポレイテッド | ＥＰ２−受容体作用薬としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似物 |
| ES2246419T3 (es) | 2001-11-05 | 2006-02-16 | Allergan, Inc. | Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2. |
| AU2002348948A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Pharmaceutical compositions and methods for administering EP2 receptors selective agonists |
| JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
| AU2003252149A1 (en) | 2002-08-02 | 2004-02-23 | Applied Research Systems Ars Holding N.V. | Thiophene and furan derivatives as prostaglandin agonists and use thereof |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0329620D0 (en) | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
| US7326732B2 (en) * | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
-
2006
- 2006-08-09 CA CA002618486A patent/CA2618486A1/en not_active Abandoned
- 2006-08-09 US US12/063,421 patent/US8080567B2/en not_active Expired - Fee Related
- 2006-08-09 EP EP06779103A patent/EP1951701A2/en not_active Withdrawn
- 2006-08-09 JP JP2008525637A patent/JP2009505973A/ja active Pending
- 2006-08-09 WO PCT/GB2006/002979 patent/WO2007017687A2/en not_active Ceased
- 2006-08-09 AU AU2006277786A patent/AU2006277786B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547716A5 (enExample) | ||
| JP2008512380A5 (enExample) | ||
| JP2009534468A5 (enExample) | ||
| JP2015520738A5 (enExample) | ||
| CA2540163A1 (en) | Thrombin receptor antagonists | |
| JP2009544602A5 (enExample) | ||
| JP2023518948A5 (enExample) | ||
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2004535466A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| TN2010000256A1 (en) | Organic compound | |
| JP2010511013A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2010509284A5 (enExample) | ||
| EP1695955A4 (en) | COMPOUNDS WITH LYSOPHOSPHATIDYLIC ACID RECEPTANT AGONISM AND USES THEREOF | |
| JP2009543795A5 (enExample) | ||
| JP2008546770A5 (enExample) | ||
| EA201001127A1 (ru) | Производные пиридина | |
| JP2008543860A5 (enExample) | ||
| JP2007519721A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| JP2017509611A5 (enExample) | ||
| JP2016526023A5 (enExample) | ||
| JP2007538031A5 (enExample) |